ProMIS Neurosciences, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

WARRANTS

WARRANTS

9 Months Ended

Sep. 30, 2025

7.	WARRANTS

As of September 30, 2025, outstanding Common Share warrants and exercise prices related to unit offerings are as follows:


Exercise	Number of
Price $	Warrants	Expiry date
C$12.00	279,613	November 2025
US$2.02	7,854,656	January 2026
US$12.60	524,088	August 2026
US$9.60	146,744	August 2026
US$2.02	7,854,656	January 2027
US$7.50	345,938	April 2028
US$6.10	69,188	April 2028
US$1.75	11,227,714	February 2029
US$2.50	7,854,656	July 2029
US$1.25	28,233,180	July 2030
US$0.01	1,866,826	None
	66,257,259

During the three and nine months ended September 30, 2025, 1,279,923 pre-funded warrants, including 984,736 issued in the July 2025 RD Offering, were exercised for gross proceeds of $3,050. Refer to Note 6 for discussion on the discounted exercise of 8,411,214 July 2024 PIPE warrants on July 22, 2025, discounted exercise of 10,410,906 July 2024 PIPE warrants on July 28, 2025, issuance of 12,616,820 new warrants on July 22, 2025, and issuance of 15,616,360 new warrants on July 28, 2025.